Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 176Neoplasms 173Carcinoma, Non-Small-Cell Lung 152Prostatic Neoplasms 108Colorectal Neoplasms 105Lung Neoplasms 91Ovarian Neoplasms 82Neoplasm Metastasis 76Multiple Myeloma 72Pancreatic Neoplasms 70Leukemia, Myeloid, Acute 63Endometrial Neoplasms 49Squamous Cell Carcinoma of Head and Neck 47Stomach Neoplasms 45Melanoma 44Lymphoma 44Glioblastoma 42Carcinoma, Renal Cell 42Recurrence 41Brain Neoplasms 41Urinary Bladder Neoplasms 39Carcinoma, Hepatocellular 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Sarcoma 37Glioma 36Lymphoma, Non-Hodgkin 35Hematologic Neoplasms 35Leukemia, Lymphocytic, Chronic, B-Cell 34Esophageal Neoplasms 33Small Cell Lung Carcinoma 31

Interventions

atezolizumab 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Extensive Stage Lung Small Cell Carcinoma × 30 days × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡